RIOX2 and prostate carcinoma: Interestingly, among these Myc family members, only c-Myc was significantly upregulated in prostate cancers compared to benign compartments (Figures 6J, K), suggesting that c-Myc is potentially a major regulator of RIOX2 expression in prostate cancer.